A Clinical Pharmacology of KHK4827 in Healthy Volunteers and Subject With Moderate to Severe Psoriasis
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This is a randomized, placebo-controlled, ascending single dose study of KHK4827 to evaluate
safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous or intravenous
administration of KHK4827 in healthy male subjects or moderate to severe psoriasis patients.
Phase:
Phase 1
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.